Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid

Blood

Volumn 118, Issue 5, 2011, Pages 1248-1254

  Park, Jae H ^a   Qiao, Baozhen ^b   Panageas, Katherine S ^a   Schymura, Maria J ^b   Jurcic, Joseph G ^a   Rosenblat, Todd L ^a   Altman, Jessica K ^c   Douer, Dan ^a   Rowe, Jacob M ^d   Tallman, Martin S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG BIOAVAILABILITY; FEMALE; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SURVIVAL;

EID: 79961092821     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-346437     Document Type: Article

References (41)

1. Bennett JM, Catovsky D, Daniel MT, et al. A variant form of hypergranular promyelocytic leukaemia (M3). Br J Haematol. 1980;44(1):169-170. (Pubitemid 10201720)
2. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) cooperative group. Br J Haematol. 1976;33(4):451-458.
3. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood. 1992;79(3):543-553.
4. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet. 1977;1(8010):549-550. (Pubitemid 8045927)
5. Grignani F, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993;74(3):423-431. (Pubitemid 23244608)
6. Burnett AK, Hills RK, Grimwade D, et al. Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promyelocytic leukaemia with lower toxicity and resource usage: preliminary results of the MRC AML15 Trial [abstract]. Blood. 2007;110(11):Abstract 589.
7. Avvisati G, Lo Coco F, Diverio D, et al. AIDA (alltrans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood. 1996;88(4):1390-1398. (Pubitemid 26276815)
8. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(15):1021-1028. (Pubitemid 27430519)
9. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997;90(3):1014-1021.
10. Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol. 1998;16(1):78-85. (Pubitemid 28041582)
11. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999;94(4):1192-1200. (Pubitemid 29380399)
12. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood. 1999;94(9):3015-3021. (Pubitemid 29512705)
13. Surveillance Epidemiology End Results (SEER) Program. SEER*Stat Database: Incidence, SEER
14. Regs Research Data, Nov 2009 Sub (1992-2007), Linked To County Attributes, Total U.S., 1969-2007 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission. http://www.seer.cancer.gov. Accessed September 2010.
15. Percy C SK, Whelan S, Parkin DM, Jack A, Fritz A. International Classification of Diseases for Oncology (ICD-O). 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
16. Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst. 2010;102(20):1584-1598.
17. Surveillance Research Program, National Cancer Institute SEER*Stat software version 6.6.2. http://www.seer.cancer.gov/seerstat. Accessed September 2010.
18. Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010;116(17):3171-3179.
19. Breccia M, Latagliata R, Cannella L, Minotti C, Meloni G, Lo-Coco F. Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica. 2010;95(5):853-854.
20. Burnett AK HR, Grimwade D, et al. Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promylocytic leukemia with lower toxicity and resource usage: preliminary results of the MRC AML 15 trial. Blood. 2007;110:181a.
21. Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood. 1990;75(11):2112-2117. (Pubitemid 20181160)
22. Cordonnier C, Vernant JP, Brun B, et al. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer. 1985;55(1):18-25. (Pubitemid 15198193)
23. Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood. 1989;73(5):1116-1122. (Pubitemid 19107411)
24. Micol J-B, Raffoux E, Boissel N, et al. Do early events excluding patients with acute promyelocytic leukemia (APL) from trial enrollment modify treatment result evaluation? Real-life management of 100 patients referred to the University Hospital Saint-Louis between 2000 and 2010 [abstract]. Blood. 2010;116(21):Abstract 1083.
25. BensonAB III, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1991;9(11):2067-2075.
26. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875-1891.
27. Juliusson GAP, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179.
28. Jeddi R, Kacem K, Ben Neji H, et al. Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia. Hematology. 2008;13(3):142-146.
29. Alizadeh AA, McClellan JS, Gotlib JR, et al. Early mortality in acute promyelocytic leukemia may be higher than previously reported [abstract]. Blood. 2009;114(22):Abstract 1015.
30. Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128-1134.
31. Rego EM, Kim HT, Ruiz-Arguelles GJ, et al. Improving the treatment outcome of acute promyelocytic leukemia in developing countries through International Cooperative Network. Report on the International Consortium on Acute Promyelocytic Leukemia Study Group [abstract]. Blood. 2009;114(22): Abstract 6.
32. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110(5):588-636. (Pubitemid 39036178)
33. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620-625.
34. Falini B, Flenghi L, Fagioli M, et al. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood. 1997;90(10):4046-4053. (Pubitemid 27484059)
35. Dimov ND, Medeiros LJ, Kantarjian HM, et al. Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M.D. Anderson Cancer Center experience of 349 patients. Cancer. 2010;116(2):369-376.
36. Sanz MA, Montesinos P, Rayon C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115(25):5137-5146.
37. Lengfelder E, Haferlach C, Saussele S, et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia. 2009;23(12):2248-2258.
38. Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA. Representation of older patients in cancer treatment trials. Cancer. 1994;74(7 suppl):2208-2214. (Pubitemid 24304400)
39. Hutchins LF, Unger JM, Crowley JJ, Coltman CAJr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061-2067. (Pubitemid 30035956)
40. Sanz MA, Vellenga E, Rayon C, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood. 2004;104(12):3490-3493.
41. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7):3395-3402.